On the heels of receiving new certification from the Foundation for the Accreditation of Cellular Therapy (FACT) to perform adult allogeneic transplants, Perlmutter Cancer Center is significantly expanding its Blood and Marrow Transplant Program.
The program performs autologous and allogeneic transplants for adults and autologous transplants for children to treat the full spectrum of blood-borne cancers, including leukemia, lymphoma, and multiple myeloma. Autologous transplants involve using a patient’s own blood and blood by-products, whereas allogeneic transplants use those from an appropriate donor.
The Blood and Marrow Transplant Program is led by nationally renowned hematologist–oncologist Samer Al-Homsi, MD, MBA, who joined Perlmutter Cancer Center—one of the 70 cancer centers across the country designated by the National Institutes of Health—in June 2017. Just in the past 12 months, more than 70 patients have received blood and marrow transplants at Perlmutter Cancer Center, which are performed in the specially designed Rita J. and Stanley H. Kaplan Stem Cell and Bone Marrow Transplant Center, located in the brand-new Kimmel Pavilion on NYU Langone’s main campus in Manhattan.